Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05986682 · OUTCOME

Treatment Characteristics: Discontinuation of BLENREP Treatment

Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma · Source last updated 2025-02-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.

What was measured

Number of participants who discontinued treatment with BLENREP by reason.

Groups in this outcome

Multiple Myeloma/Blenrep Participants

Participants with relapsed and/or refractory multiple myeloma who were treated with Belantamab Mafodotin - blmf (BLENREP) in the DCI Oncology outpatient clinics between August 5, 2020 and November 7, 2023

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Multiple Myeloma/Blenrep Participants30

Reported measurements

Discontinuations for any reason
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Multiple Myeloma/Blenrep Participants26Not reportedNot reportedNot reportedNot reported
Discontinuation for Disease Progression
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Multiple Myeloma/Blenrep Participants22Not reportedNot reportedNot reportedNot reported
Discontinuation for Corneal or other ocular toxicity
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Multiple Myeloma/Blenrep Participants4Not reportedNot reportedNot reportedNot reported
Discontinuation for Physician/Patient choice
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Multiple Myeloma/Blenrep Participants3Not reportedNot reportedNot reportedNot reported
Discontinuation for other reason
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Multiple Myeloma/Blenrep Participants3Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        26
    title
    Discontinuations for any reason
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        22
    title
    Discontinuation for Disease Progression
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        4
    title
    Discontinuation for Corneal or other ocular toxicity
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        3
    title
    Discontinuation for Physician/Patient choice
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        3
    title
    Discontinuation for other reason
denoms
  1. counts
    1. group Id
      OG000
      value
      30
    units
    Participants
description
Number of participants who discontinued treatment with BLENREP by reason.
groups
  1. description
    Participants with relapsed and/or refractory multiple myeloma who were treated with Belantamab Mafodotin - blmf (BLENREP) in the DCI Oncology outpatient clinics between August 5, 2020 and November 7, 2023
    id
    OG000
    title
    Multiple Myeloma/Blenrep Participants
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.
title
Treatment Characteristics: Discontinuation of BLENREP Treatment
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice